kidney disease and liver outcomes

FLOW trial results, eGFR trajectories, and emerging MASH evidence

kidney disease and liver outcomes

the FLOW trial established semaglutide as the first GLP-1 receptor agonist to demonstrate kidney-specific benefits in patients with type 2 diabetes and chronic kidney disease. this unit covers the primary and secondary renal endpoints, eGFR slope changes, and the parallel evidence accumulating for MASH and liver fibrosis resolution.

the paid sections walk through FLOW's 24% composite kidney endpoint reduction, the mechanisms behind eGFR slope preservation, and why the phase 2 MASH resolution data led to Wegovy's August 2025 accelerated approval for liver disease.

Interactive Visualization

explore kidney function trajectories and outcome event curves from the FLOW trial.

FLOW trial kidney function curves

Knowledge Check

test what you learned in this unit.

Practice Exercises

reinforce the key renal and hepatic concepts before moving on.